SCHEMBL3368550

SCHEMBL3368550

O=C(Nc1cccc(Cl)c1)c1cn2cc(Cl)ccc2n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 2/20 0.59
DGAT1 O75907 1/20 0.57
MLLT1 Q03111 1/20 0.55
NPC1 O15118 5/20 0.54
RAB9A P51151 5/20 0.54
AHR P35869 1/20 0.54
GRM4 Q14833 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
THRB P10828 1/20 0.51
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
CYP2C9 P11712 1/20 0.51
NR4A2 P43354 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
P2RX1 P51575 1/20 0.50
P2RX4 Q99571 1/20 0.50
P2RX7 Q99572 1/20 0.50
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
LMNA P02545 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3371739 0.89 RAB9A (0.51) EGLN1DGAT1NPC1RAB9AKMT2A
SCHEMBL16762962 0.89 EGLN1 (0.56) EGLN1DGAT1MLLT1NPC1RAB9A
SCHEMBL3367654 0.88 RAB9A (0.70) EGLN1DGAT1NPC1RAB9ACYP2C9
SCHEMBL3365500 0.87 NPC1 (0.55) EGLN1DGAT1MLLT1NPC1RAB9A
SCHEMBL3368103 0.86 KMT2A (0.56) EGLN1NPC1RAB9AGRM4THRB
SCHEMBL3368010 0.85 NPC1 (0.57) EGLN1NPC1RAB9AKMT2AMEN1
SCHEMBL3775932 0.82 CYP11B2 (0.58) NPC1RAB9AKMT2AMEN1CYP2C9
SCHEMBL3367808 0.82 EGLN1 (0.72) EGLN1DGAT1NPC1RAB9AKMT2A
SCHEMBL3367641 0.81 EGLN1 (0.62) EGLN1DGAT1MLLT1KMT2AMEN1
SCHEMBL8222627 0.80 NPC1 (0.52) EGLN1DGAT1NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2041133-B1 DERIVATIVES OF IMIDAZO [1,2-A]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI AVENTIS (FR) 2010-10-13 EP claimed
US-7704989-B2 Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics SANOFI-AVENTIS (FR) 2010-04-27 US claimed
US-20090149441-A1 DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2009-06-11 US claimed
EP-2041133-B1 DERIVATIVES OF IMIDAZO [1,2-A]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI AVENTIS (FR) 2010-10-13 EP disclosed
US-7704989-B2 Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics SANOFI-AVENTIS (FR) 2010-04-27 US disclosed
US-20090149441-A1 DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2009-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149441-A1 DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS NR4A2, NR4A3, NCOR1 EGLN1 3911/4885DGAT1 4417/4885MLLT1 640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.